These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 17203006

  • 1. Drug Insight: resistance to methotrexate and other disease-modifying antirheumatic drugs--from bench to bedside.
    van der Heijden JW, Dijkmans BA, Scheper RJ, Jansen G.
    Nat Clin Pract Rheumatol; 2007 Jan; 3(1):26-34. PubMed ID: 17203006
    [Abstract] [Full Text] [Related]

  • 2. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis.
    Tsujimura S, Saito K, Nawata M, Nakayamada S, Tanaka Y.
    Ann Rheum Dis; 2008 Mar; 67(3):380-8. PubMed ID: 17660216
    [Abstract] [Full Text] [Related]

  • 3. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK, Furst DE.
    Rheum Dis Clin North Am; 2007 Feb; 33(1):197-217. PubMed ID: 17367700
    [Abstract] [Full Text] [Related]

  • 4. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient.
    Ranganath VK, Furst DE.
    Clin Geriatr Med; 2005 Aug; 21(3):649-69, viii. PubMed ID: 15911212
    [Abstract] [Full Text] [Related]

  • 5. Pharmacogenomics in rheumatoid arthritis.
    Ranganathan P.
    Methods Mol Biol; 2008 Aug; 448():413-35. PubMed ID: 18370240
    [Abstract] [Full Text] [Related]

  • 6. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
    Kitahara K, Kawai S.
    Curr Opin Rheumatol; 2007 May; 19(3):238-45. PubMed ID: 17414949
    [Abstract] [Full Text] [Related]

  • 8. Disease-modifying antirheumatic drugs.
    Brasington R.
    J Hand Surg Am; 2009 Feb; 34(2):347-8. PubMed ID: 19181237
    [No Abstract] [Full Text] [Related]

  • 9. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.
    van Roon EN, van den Bemt PM, Jansen TL, Houtman NM, van de Laar MA, Brouwers JR.
    Clin Ther; 2009 Aug; 31(8):1737-46. PubMed ID: 19808132
    [Abstract] [Full Text] [Related]

  • 10. Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.
    Nandi P, Kingsley GH, Scott DL.
    Curr Opin Rheumatol; 2008 May; 20(3):251-6. PubMed ID: 18388514
    [Abstract] [Full Text] [Related]

  • 11. Expression of resistance markers to methotrexate predicts clinical improvement in patients with rheumatoid arthritis.
    Wolf J, Stranzl T, Filipits M, Pohl G, Pirker R, Leeb B, Smolen JS.
    Ann Rheum Dis; 2005 Apr; 64(4):564-8. PubMed ID: 15345497
    [Abstract] [Full Text] [Related]

  • 12. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
    James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, Proudman SM.
    J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of rheumatoid arthritis].
    Babić-Naglić D.
    Reumatizam; 2003 Apr; 50(2):22-7. PubMed ID: 15098369
    [Abstract] [Full Text] [Related]

  • 14. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
    Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Häntzschel H, Baerwald CG.
    J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
    [Abstract] [Full Text] [Related]

  • 15. The use of low dose methotrexate in rheumatoid arthritis - are we entering a new era of therapeutic drug monitoring and pharmacogenomics?
    Stamp L, Roberts R, Kennedy M, Barclay M, O'Donnell J, Chapman P.
    Biomed Pharmacother; 2006 Dec; 60(10):678-87. PubMed ID: 17071051
    [Abstract] [Full Text] [Related]

  • 16. [Pharmacogenomics of methrotexate: a strategy for a customized therapeutic scheme for patients with rheumatoid arthritis].
    Mena-Ramírez JP, Salazar-Páramo M, Dávalos-Rodríguez IP.
    Gac Med Mex; 2008 Dec; 144(5):449-51. PubMed ID: 19043967
    [Abstract] [Full Text] [Related]

  • 17. Disease-modifying antirheumatic drugs, including methotrexate, gold, sulfasalazine, antimalarials, and D-penicillamine.
    Conaghan PG, Brooks P.
    Curr Opin Rheumatol; 1996 May; 8(3):176-82. PubMed ID: 8796975
    [Abstract] [Full Text] [Related]

  • 18. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS, Taylor WJ, CASPAR Study Group.
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.